Knowledge database

Search for peer-reviewed ISCOM articles

To date, over 450 publications describe the immunopotentiating properties of ISCOM adjuvants in terms of antibody responses, cellular responses, cytokine and chemokine production, and protection against infection.

Explore the ISCOM Knowledge Base

Immunology research

Try the next-generation ISCOMS

The new generation of ISCOM technology has opened up new applications in immunological research by overcoming drawbacks once associated with problematic formulations. Isconova’s next-gen adjuvant is easily handled with any antigen.

Try the state-of-the-art adjuvants in your research

Companion animals

A license to care

Isconova’s platform technology is available for licensing for many veterinary vaccine development segments. Our tailored business collaboration models are designed to fit your specific requirements and circumstances.

View available licensing options

Livestock

Serve and protect

We can help improve and/or develop your vaccine products. Many livestock segments are open for collaboration and licensing.

View available licensing options

Human applications

Isconova's recent development of its adjuvant technology platform opens up new opportunities to develop human vaccines with outstanding performance and safety. We invite interested partners to explore the possibilities through research collaboration projects.

Current vaccines on the market

  • Canvac CCi® – Bordetella bronchiseptica (2007, Pfizer)
  • Equilis® Prequenza – Equine influenza (2006, Intervet, now part of Schering-Plough)
  • Pestigard® – Bovine BVDV (2003, Pfizer)
  • Equity® – Equine LHRH (2002, Pfizer)
  • Equip® – Equine influenza (1993, Schering-Plough. From Oct. 2008, Pfizer)

AbISCO compared to other adjuvants

The AbISCO® adjuvant consistently induces the highest proliferation index and high production levels of antibodies.

Two cornerstone patent applications granted in Europe

Thursday, January 22nd, 2009

Two cornerstone patent applications covering Isconova’s most recent development of its adjuvant technology platform with improved safety and efficacy has been granted in Europe.
The new formulations increase the adjuvant performance safety window by an order of magnitude, a result that has been verified in several species. The increased performance and safety is not limited to [...]